Intuitive Surgical shares are down 3%

Intuitive Surgical, Inc. (ISRG) shares fell 3% on March 12, 2026, extending a three-month decline of 13.4% amid concerns over margin pressures and competitive dynamics in the robotic surgery market according to market analysis. The recent drop followed the company's preannouncement of 2026 procedure growth guidance, which projected 13-15% growth—below the 15.5-17% range previously raised for 2025. Procedure growth is critical for ISRG, as recurring revenue from single-use instruments and accessories accounts for 85% of total sales as reported.

The stock's underperformance reflects broader challenges, including a 200-300 basis points contraction in adjusted gross margin anticipated for 2025, driven by tariffs, product mix shifts, and the high cost of its latest da Vinci 5 system. While ISRG's leading market position in robotic surgery—dominating U.S. and global adoption—supports long-term top-line growth, near-term earnings face headwinds. Competitors like Medtronic (MDT) and Johnson & Johnson (JNJ) have gained traction with lower-cost alternatives, such as Medtronic's Hugo system and J&J's AI-enhanced Ottava platform according to industry reports.

Valuation concerns also weigh on investor sentiment, with ISRG trading at a forward P/E of 50.56x, well above the sector average of 27.51x. Despite robust procedure recovery post-pandemic and strong international demand for certain procedures, budget constraints in key markets and the impact of obesity-targeting drugs on bariatric surgeries add uncertainty. Analysts suggest investors monitor evolving demand trends and margin resilience before making decisions, as ISRG's stock remains below both its 50-day and 200-day moving averages according to technical analysis.